Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Evidence Tier Mol
It may also help to boost compliance when injectables are not preferred and could be priced lower to reach a broader swathe of patients, especially outside the United States. Morgan Stanley: A broader and more lasting behavioral shift According to recent research from Morgan Stanley, its biopharma analysts expect the US anti-obesity medication (AOM) patient pool to increase fivefold to 24 million people (7% of the US population) over the next decade
10.1161/CIRCULATIONAHA.107.739938 69
Take the first step toward a healthier, more vibrant you
Some users report transient increases in blood pressure and heart rate after injection
Can a pharmaceutical company afford not to participate in a segment that is supposed to be one of the biggest in India and expanding globally too
